Fig 7.

(A) ChIP analysis of histone modification at the CCR5 promoter in Jurkat cells, after treatment with Zebularine, DZNep and MS275. The treatment of Jurkat cells results in an increase of AcH3 at the CCR5 promoter. Repressive marks at the CCR5 chromatin are not influenced much by the treatment, although a minor decrease in 3MeK27H3 can be noted. (B) ChIP analysis of the CCR5 promoter for CREB-1 and RNA polymerase II after treatment with small molecule inhibitors in Jurkat, compared to both naïve and activated T cells. Treatment of Jurkat cells with Zebularine, DZNep and MS275 slightly increases CREB-1 in chromatin of the CCR5 promoter. In both naïve and activated T cells higher levels of chromatin-associated CREB-1 can be found. Compared to naïve T cells, there is an increase of CREB-1 in activated T cells. Treatment of Jurkat cells with small molecule inhibitors increases RNA polymerase II recruitment to the CCR5 promoter to levels similar of naïve T cells. In comparison to activated T cells, the levels of RNA polymerase II in the CCR5 promoter region of treated Jurkat cells are modest.